ClinicalTrials.gov
public full text
Public Domain
LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes
This is an investigator-led prospective, randomized, open label, parallel study to explore and evaluate the therapeutic effects of Liraglutide, Empagliflozin and Linagliptin on the cognitive function in T2DM patients with mild cognitive impairment (MCI), consisting of a 48-week core study followed by a 28-week extension phase.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Antidiabetic medications and risk of cognitive disorders in type 2 diabetes: A retrospective cohort study#483556
- Effects of Yeast Beta-glucan on Cognitive Function in Patients With Mild Cognitive Impairment#885955
- Balanced polyunsaturated fatty acids diet prevents the D-galactose-induced neuroinflammation and cognitive impairments#145014
- Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin#245462
- Nurse-led non-pharmacological interventions for cognitive improvement in dementia patients: a systematic review and meta-analysis of randomized controlled trials.#439210
Record · ID 1139635
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive